Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of January
12, 2019, the Board of Directors (the “Board”) of Bioanalytical Systems, Inc. (the “Company”) elected Robert
Leasure, Jr., age 59, President and Chief Executive Officer and as a director of the Company.
Mr. Leasure serves
as the managing partner and president of LS Associates LLC (“LS”), a management and turnaround firm formed in 2002.
From September of 2016 until Mr. Leasure’s election, the Company engaged LS as a financial consultant and paid LS fees in
the amount of $317,681.57 in fiscal 2018. Mr. Leasure’s interest in those fees amounts to approximately $238,261. The Board
believes Mr. Leasure's experience working with management teams in areas including strategic planning and implementation, problem
solving, operations, mergers and acquisitions and financial transactions, and in particular Mr. Leasure’s experience leading
the Company’s turnaround, well situate him for his role as President and Chief Executive Officer and as a director. There
are no arrangements or understandings between Mr. Leasure and any other persons pursuant to which he was elected as an officer
or director and Mr. Leasure has no family relationships with any other director or executive officer of the Company.
In connection with
his election, the Company entered into an Employment Agreement (the “Employment Agreement”) with Mr. Leasure. Pursuant
to the Employment Agreement, Mr. Leasure agrees to serve as the President and Chief Executive Officer of the Company for a term
ending on December 31, 2019, subject to extension for successive one-year periods thereafter upon the mutual agreement of the parties.
Under the Employment Agreement, Mr. Leasure will (a) be entitled to receive an initial base salary at a rate of $270,000 per year,
(b) have an annual incentive opportunity of up to 33% of his base salary for the year, (c) be entitled to receive a cash bonus
in the annual amount of $45,000, payable quarterly based upon the achievement of Board-approved Company goals, and (d) be entitled
to vacation in accordance with Company policy and reimbursement for ordinary and necessary business expenses. Mr. Leasure will
also be entitled to participate in the Company’s benefit plans and programs provided to Company executives generally, subject
to eligibility requirements and other terms and conditions of those plans. Also under the terms of the Employment Agreement and
under the Company’s 2018 Equity Incentive Plan (the “Plan”), on the first day of his employment, Mr. Leasure
received (i) an inducement grant of 34,615 common shares of the Company, (ii) 10,000 restricted common shares of the Company and
(iii) options to purchase 55,000 of the Company’s common shares. The restricted common shares and stock options are subject
to vesting and forfeiture, including in the event of Mr. Leasure’s termination by the Company for cause or Mr. Leasure’s
resignation other than for good reason (each as defined in the Employment Agreement).
The Employment Agreement
provides for certain non-competition, non-solicitation and confidentiality undertakings. Should Mr. Leasure’s employment
be terminated by reason of Mr. Leasure’s death, by the Company without cause or in the event of Mr. Leasure’s disability
(as defined in the Employment Agreement), or by Mr. Leasure for good reason, Mr. Leasure or his estate would be entitled to his
base salary and a prorated portion of his annual incentive award for the year in which termination occurs, in each case through
the effective date of the termination of his employment. If Mr. Leasure’s employment is terminated by the Company other than
for cause, or by Mr. Leasure for good reason, in either case within 12 months after a change in control (as defined in the Plan)
(i) the Company would pay to Mr. Leasure in a lump sum, as severance compensation, an amount equal to one times his base salary
then in effect plus one times his annual incentive compensation paid for the Company’s last calendar year, (ii) all unvested
outstanding options to purchase the Company’s common shares, unvested awards of restricted stock and unvested awards of restricted
stock units held by Mr. Leasure would vest immediately prior to the termination and, in the case of any such options, remain exercisable
for a period of 30 days following the effective date of the termination, and (iii) Mr. Leasure would be entitled to receive, a
pro-rata portion of the number of performance shares that would have been earned by Mr. Leasure if the performance conditions related
thereto were satisfied at the target level for such awards and Mr. Leasure had been employed on the date required to earn such
shares.
The foregoing summary
of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Employment Agreement,
a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2019.